CA-LATTICEFLOW-AI
12.3.2024 12:31:33 CET | Business Wire | Press release
LatticeFlow AI, the leading platform empowering AI teams to build performant, safe, and trustworthy AI solutions, proudly announces the creation of its advisory board and the appointment of two AI luminaries, Milena Marinova and Jean-Luc Chatelain, as founding members.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240312894740/en/
LatticeFlow AI welcomes Milena Marinova and Jean-Luc Chatelain to its advisory board (Photo: Business Wire)
Milena Marinova, brings a wealth of experience and expertise in software development and in the field of AI, ML and GenAI, with over 15 years of launching innovative AI products and solutions globally. Most recently she established the AI Acceleration Studio at Microsoft and currently serves as its Vice President. Milena’s visionary leadership in building intelligent AI systems, emphasizing experimentation and evaluation for human and AI collaboration, aligns with LatticeFlow AI’s mission of delivering trustworthy AI solutions at scale.
“In the era of AI adoption, building responsible AI is paramount to the success of these deployments,” says Milena. “I’m happy to become an advisor to LatticeFlow AI and help advance the vision of its founders and their strong commitment to building tools that ensure AI safety and trust.”
Jean-Luc Chatelain, former CTO of Applied Intelligence at Accenture, is also a seasoned AI expert with a deep understanding of the challenges and opportunities in building and operationalizing mission-critical AI systems for large-scale organizations.
“Trust is the foundation of a successful AI platform,” says Jean-Luc. “I am thrilled to join the LatticeFlow AI’s advisory board and help the company realize its mission of enabling enterprises to build and deploy safe and trustworthy AI systems that unlock business value.”
Milena’s outstanding leadership in pioneering groundbreaking AI solutions, coupled with her profound expertise in machine learning, AI, and deep neural networks, will be invaluable in advancing LatticeFlow AI’s vision of bringing mission-critical AI solutions to market. Similarly, Jean-Luc’s expertise in constructing AI systems for large organizations across the globe, grounded in trust and responsibility, will be pivotal in helping LatticeFlow AI bolster the safety and reliability of its solutions.
“We are honored to welcome Milena and Jean-Luc to our advisory board,” shared LatticeFlow AI’s co-founders Petar Tsankov (CEO) and Pavol Bielik (CTO). “Their collective expertise, aligned with our vision for responsible AI adoption, will be instrumental in guiding our long-term growth strategy in the years to come.”
The creation of LatticeFlow AI’s top-tier AI advisory board follows the expansion of LatticeFlow AI into the US market and the appointment of Tom Ulrich as Senior Vice President and General Manager of LatticeFlow North America.
About LatticeFlow AI
LatticeFlow AI offers a cutting edge AI platform that empowers enterprise teams to build performant, safe, and trustworthy AI at scale. Our platform is designed to unlock the full value of AI by systematically addressing critical model and data issues through automated processes and intelligent workflows across your entire AI lifecycle.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240312894740/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168 for the Treatment of Ataxia Telangiectasia (A-T)13.7.2026 14:32:00 CEST | Press release
Regulatory recognition in the United States and Europe supports the development of NB4168, a novel small molecule candidate for a rare pediatric disease with no approved treatments Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that the U.S. Food & Drug Administration (FDA) granted Rare Pediatric Disease (RPD) Designation for its proprietary lead small molecule drug candidate NB4168 for the treatment of Ataxia Telangiectasia (A-T). NB4168 is an oral small molecule therapy engineered to deliver substantially greater nicotinamide riboside (NR) exposure than conventional NR while maintaining a differentiated pharmacokinetic and safety profile. In addition, the European Medicines Agency (EMA) has granted Orphan Medicinal Product Designation (OMPD) to NB4168 for the treatment of A-T, providing regulatory recognition in the European Union and further supporting the Company'
SLB OneSubsea Awarded EPC Contract for Eni’s Baleine Phase 3 Project Offshore Côte d'Ivoire13.7.2026 14:00:00 CEST | Press release
Integrated subsea production system and local capabilities enable accelerated deepwater development Global energy technology company SLB (NYSE: SLB) announced today that its OneSubsea™ joint venture has been awarded a major multi-well engineering, procurement, and construction (EPC) contract by Eni for Phase 3 of the deepwater Baleine project offshore Côte d’Ivoire. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260712734539/en/ SLB OneSubsea™ joint venture has been awarded a major multi-well engineering, procurement, and construction (EPC) contract by Eni for Phase 3 of the deepwater Baleine project offshore Côte d’Ivoire. Under the contract, SLB OneSubsea will deliver complete subsea production systems (SPS) for 13 wells, reinforcing its role as a core technology and execution partner on one of the most strategically significant offshore developments currently underway in the region. The EPC scope includes subsea trees, um
HistoSonics Receives CE Mark, Unlocking Access Across Europe and Accelerating Global Commercialization of the Edison® Histotripsy Platform13.7.2026 14:00:00 CEST | Press release
HistoSonics, today announced that the company has received CE Mark approval in Europe for its Edison® System, enabling commercialization of the company’s non-invasive histotripsy technology in Europe and other markets that recognize the CE Mark. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260713505048/en/ HistoSonics Edison® Histotripsy System The Edison System is a novel, non-invasive, image guided platform that is intended for the destruction of liver tumors, including the partial or complete destruction of unresectable liver tumors. It uses the mechanical properties of focused ultrasound, called histotripsy, to liquefy and destroy unwanted tissue and tumors in a single procedure without the need for invasive procedures or radiation, and with potentially fewer side effects than traditional therapies. CE Mark approval follows an increasing number of regulatory clearances and was supported by a growing body of clinical ev
Esri Introduces ArcGIS Velocity for ArcGIS Enterprise to Power Real-Time GIS Operations13.7.2026 14:00:00 CEST | Press release
ArcGIS Velocity Brings Real-Time Data Ingestion, Analysis, and Automated Alerting to ArcGIS Enterprise Deployments Esri announces that ArcGIS Velocity is now available for ArcGIS Enterprise, enabling real-time data analytics and automated actions in self-hosted environments. This capability’s new deployment unifies real-time workflows across ArcGIS Online and ArcGIS Enterprise. This update benefits organizations across industries: public safety, transportation, logistics, and more. Esri, the global leader in location intelligence, has released for general availability ArcGIS Velocity for ArcGIS Enterprise for self-hosted deployments on Windows and Linux. This enables organizations to leverage Velocity from secure on-premises and private cloud environments. Available as software as a service (SaaS) for ArcGIS Online and now for self-hosted environments in ArcGIS Enterprise, Esri’s next-generation geospatial capability delivers real-time analytics on streaming, Internet of Things (IoT),
Agenus Announces Oversubscribed Private Placement of Up to $340 Million to Advance Registrational ROBBIN Trial of Neoadjuvant BOT+BAL in MSS Colon Cancer13.7.2026 12:00:00 CEST | Press release
$85M upfront financing, along with up to $255 million upon exercise of purchase warrants, is expected to fund ROBBIN1, Agenus' registrational Phase 3 trial of neoadjuvant botensilimab and balstilimab (BOT+BAL) in microsatellite-stable (MSS) colon cancer Transaction is structured to fund Agenus through key value-inflection points, including interim topline pathologic response data and interim and final event-free survival (EFS) analyses, with proceeds to fund Agenus operations through year-end 2031, assuming full warrant exercise ROBBIN target population in MSS colon cancer represents a >$7 billion addressable annual sales opportunity in the US for which no new therapies have been approved in over 20 years2,3 To focus resources on the neoadjuvant opportunity, Agenus is discontinuing financial support for the ongoing BATTMAN Phase 3 study in late-line metastatic MSS colorectal cancer Company to host conference call and webcast today at 8:30 a.m. ET Agenus Inc. (Nasdaq: AGEN), a leader in
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom